Table 1.

Most common conditions within each comorbidity group classification reported by the investigator at core baseline (occurring in ≥5% of patients in any treatment group). Comorbidities listed as reported by the investigator. Data based on preferred terms from patient medical history. Complete list of comorbidities for each comorbidity group classification is provided in the Supplementary Appendix.

Comorbidity, n (%)	Long-acting pasireotide 40 mg, n = 65	Long-acting pasireotide 60 mg, n = 65	Active control, n = 68
Vascular disorders
Hypertension	17 (26.2)	27 (41.5)	36 (52.9)
Glucose-related disorders
Diabetes mellitus	18 (27.7)	11 (16.9)	16 (23.5)
Impaired glucose tolerance	10 (15.4)	10 (15.4)	11 (16.2)
Type 2 diabetes mellitus	6 (9.2)	9 (13.8)	4 (5.9)
Lipid-related disorders
Dyslipidaemia	10 (15.4)	15 (23.1)	8 (11.8)
Hypercholesterolaemia	6 (9.2)	5 (7.7)	5 (7.4)
Endocrine-related disorders
Goitre	9 (13.8)	14 (21.5)	23 (33.8)
Hypothyroidism	10 (15.4)	10 (15.4)	12 (17.6)
Adrenal insufficiency	8 (12.3)	6 (9.2)	10 (14.7)
Hypopituitarism	7 (10.8)	4 (6.2)	5 (7.4)
Hyperprolactinaemia	5 (7.7)	5 (7.7)	3 (4.4)
Hypogonadism	4 (6.2)	6 (9.2)	5 (7.4)
Diabetes insipidus	4 (6.2)	4 (6.2)	2 (2.9)
Secondary hypothyroidism	6 (9.2)	4 (6.2)	4 (5.9)
Secondary hypogonadism	5 (7.7)	5 (7.7)	6 (8.8)
Secondary adrenocortical insufficiency	1 (1.5)	5 (7.7)	3 (4.4)
Other acromegaly-related disorders
Depression	7 (10.8)	2 (3.1)	4 (5.9)
Headache	4 (6.2)	3 (4.6)	1 (1.5)
Osteoarthritis	4 (6.2)	3 (4.6)	6 (8.8)
Carpal tunnel syndrome	5 (7.7)	1 (1.5)	5 (7.4)
Carpal tunnel decompression	3 (4.6)	2 (3.1)	4 (5.9)
Insomnia	2 (3.1)	4 (6.2)	1 (1.5)
Osteoporosis	3 (4.6)	2 (3.1)	4 (5.9)
Aortic valve incompetence	0 (0.0)	1 (1.5)	4 (5.9)
Haemangioma of the liver	0 (0.0)	0 (0.0)	4 (5.9)